#United States #Pleasanton #10x Genomics #Spatial Biology #Xenium Protein

10x Genomics Unveils Xenium Protein

10x Genomics, Inc. (Nasdaq: TXG), known for its prowess in single-cell and spatial biology, has recently elevated research capabilities with the unveiling of Xenium Protein, a game-changing product that integrates both RNA and protein analysis within a single automated workflow.

This landmark innovation is part of the Xenium Spatial platform, which is designed to provide researchers with unprecedented insights into cellular function and disease mechanisms. For the first time, scientists can now conduct RNA and protein detection concurrently within the same tissue section, making experiments more efficient and less fragmented.

The Significance of Xenium Protein

The introduction of Xenium Protein marks a pivotal step in the evolution of multiomic workflows. As technology advances, researchers can become overwhelmed by the complexities of data integration from disparate systems. The launch addresses this by streamlining the experimental design process. According to Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics, “Integrated multiomic analysis is essential to advancing our understanding of complex diseases and accelerating therapeutic discovery.”

With this technology, multiple protein subpanels are available that align seamlessly with RNA panels. These subpanels include an array of well-characterized proteins linked to critical biological processes, such as cell growth, signaling pathways, and immune responses, offering valuable applications in sectors like oncology and immunology.

Key Benefits for Researchers

One of the most compelling advantages of Xenium Protein is its ability to bypass the need for separate workflows or sample preparation. Traditionally, analyzing RNA and proteins required distinct procedures, leading to longer timelines for obtaining results. Now, researchers can perform both analyses in a single run, significantly accelerating the transition from experimentation to valuable biological insights.

This technological leap is expected to enhance early discovery processes to translational research initiatives, where insights lead to breakthroughs in understanding complex biological systems.

Dr. Julien Tessier, Principal Scientist at Sanofi, emphasizes the impact of this technology, stating, “Integrating RNA and protein analysis within the same Xenium workflow enables a comprehensive view of tissue architecture and cell-cell interactions in a single experiment.” He noted that this method eliminates challenges associated with data co-registration, further enhancing certainty in findings, particularly in target and biomarker expression research—the realm where RNA data alone often falls short.

Future Implications

The global availability of Xenium Protein positions 10x Genomics at the forefront of spatial biology. This product not only enhances the research capabilities of academic and biopharmaceutical entities but also promises to transform how scientists explore the relationships between diseases at a cellular level.

In conclusion, the launch of Xenium Protein by 10x Genomics is set to redefine research methodologies and foster a new wave of discoveries in health and disease understanding. As it integrates multiple layers of biological data, researchers are equipped with the tools needed to navigate the complexities of modern biology more effectively than ever before.

To explore more about 10x Genomics and the latest advancements in spatial biology, visit 10xgenomics.com.